在红细胞细胞中,KDM4B调节自身隐性IL6,以防止无效的红细胞形成
Zheng Peng1, Dan Su1, Jing-Jing Xu1
1CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.
Leukemia
|March 13, 2025
概括
Kdm4b基因对红细胞发育至关重要,它调节红细胞中的免疫活性. 它的缺失导致无效的红色素形成,为贫血的原因和潜在的治疗提供了洞察力.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 不有效的红色素形成 (IE) 是先天性贫血的一个关键因素,但其原因尚未完全理解.
- 新兴研究突出了核红细胞在免疫反应中的作用,这表明了IE研究的新途径.
研究的目的:
- 调查Kdm4b在红细胞发育中的作用及其与无效红细胞生成的联系.
- 阐明Kdm4b调节红细胞成熟和免疫功能的分子机制.
主要方法:
- 利用Kdm4b突变斑马鱼和小鼠来建模无效的红色素形成.
- 分析了红细胞成熟,细胞亡和免疫细胞概况.
- 研究了互白素6 (IL6) 信号通路及其下游影响,包括pStat3激活和氧化应激.
主要成果:
- 斑马鱼和小鼠的Kdm4b缺乏导致IE类型的表型,红细胞成熟受损和亡增加.
- Kdm4b通过控制IL6分泌来调节红细胞的免疫活动.
- 在Kdm4b突变体中增加的IL6促进了亲炎性髓状细胞活性和增加T细胞数量,同时还通过Il6-pStat3通路诱导氧化应激和成熟停止.
结论:
- Kdm4b在协调红细胞末端成熟和免疫功能方面发挥着至关重要的作用.
- 由于Kdm4b的失调,通过异常的IL6介导的免疫激活和氧化应激,导致无效的红色素形成.
- 这些发现为IE病因学提供了更深入的理解,并建议Kdm4b作为潜在的治疗点.
相关概念视频
Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
Role of Hematopoietic Growth Factors
1.2K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.2K
Erythropoiesis
4.0K
Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
4.0K
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
Overview of Hematopoiesis
3.7K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
3.7K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


